Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/03/2875073/0/en/Ocuphire-Pharma-to-Present-at-the-Aegis-Virtual-Conference.html
https://www.globenewswire.com/news-release/2024/04/22/2866824/0/en/Ocuphire-Pharma-Announces-APX3330-Presentation-at-ARVO-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/11/2861621/0/en/First-Patient-Enrolled-in-LYNX-2-Phase-3-Study-Evaluating-Phentolamine-Ophthalmic-Solution-0-75-PS-for-the-Treatment-of-Decreased-Visual-Acuity-Under-Low-Light-Conditions-Following.html
https://www.globenewswire.com/news-release/2024/03/08/2843088/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-Fourth-Quarter-and-Full-Year-2023-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/02/23/2834435/0/en/Ocuphire-Pharma-to-Present-in-the-BIO-CEO-Investor-Conference.html
https://www.globenewswire.com//news-release/2024/02/15/2830386/0/en/Ocuphire-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2024/02/14/2829026/0/en/Ocuphire-Pharma-Strengthens-Leadership-Team-with-Key-Appointments.html
https://www.globenewswire.com//news-release/2024/02/05/2823457/0/en/Ocuphire-Pharma-Announces-Presentation-on-APX3330-at-the-Annual-Angiogenesis-Exudation-and-Degeneration-2024-Conference.html
https://www.globenewswire.com//news-release/2024/01/24/2816080/0/en/Ocuphire-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2024/01/04/2803925/0/en/Ocuphire-Pharma-Receives-FDA-Agreement-Under-Special-Protocol-Assessment-for-LYNX-2-Phase-3-Trial-of-Phentolamine-Ophthalmic-Solution-for-the-Treatment-of-Decreased-Visual-Acuity-u.html